BioAge Labs, Inc.

NASDAQ:BIOA

Biotechnology

Healthcare
$4.77 +2.35%

+$0.47 today

Market cap
$179.59M
Beta
0.95
P/E (TTM)
-9.7
EPS (TTM)
-$2.12
52W Low $4.07High $24.00

Volume 0.64M

Average 0.46M

BIOA Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

BioAge Labs, Inc.NASDAQ: BIOA

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation grows in line with its trailing trend

Q1 FY2026 stock-based compensation of $4.26M rose 44.3% year over year, ahead of the +43.2% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 56.4% from the prior quarter. Over 3 fiscal years it compounded at +66.3% a year.

Context

  • Stock-based compensation amounted to 130.0% of revenue in FY2025.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +44.3% holds above the trailing-twelve-month pace of +43.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.26M+56.4% QoQ
Last fiscal yearDec 2025
$11.69M+67.5% YoY
LTMMar 2026
$13M+43.2% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+44.3%——
1 year+67.5%——
3-year CAGR+66.3%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
11.69M USD
Year-over-year change
+67.5%
3-year CAGR
+66.3%

Stock-Based Compensation vs competitors

How BIOA compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +43.2% is the 3rd highest of 9, against a peer median of -17.1%.
  • Stock-based compensation amounts to 126.0% of revenue for BIOA, versus a peer median of 5.1%.
BIOA Competitors
Stock-Based Compensation for BIOA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$33.74M USD-35.1%-23.4%—
CABACabaletta Bio, Inc.LTM Mar 2026$21.03M USD+1.0%+44.8%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$17.5M USD-62.1%-23.7%—
BIOABioAge Labs, Inc.LTM Mar 2026$13M USD+43.2%+66.3%126.0%
HUMAHumacyte, Inc.LTM Mar 2026$10.44M USD+45.6%+16.4%517.7%
EDITEditas Medicine, Inc.LTM Mar 2026$9.12M USD-45.7%-30.1%23.6%
ACBAurora Cannabis Inc.LTM Mar 2026CA$7.29M CAD-36.7%-24.4%2.3%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$5.91M USD—+57.3%4.4%
CGCCanopy Growth CorporationLTM Mar 2026CA$4.6M CAD+209.3%-38.3%1.5%
TKNOAlpha Teknova, Inc.LTM Mar 2026$2.42M USD+1.9%-2.6%5.8%
Peer median (excluding BIOA) —-17.1%-23.4%5.1%

Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(39.72M)(63.85M)(71.11M)(80.61M)
Depreciation & Amortization129K162K167K213K
Deferred Income Tax0000
Stock-Based Compensation2.54M3.02M6.98M11.69M
Change in Working Capital795K6.71M11.18M(11.83M)
Accounts Receivables000(769K)
Inventory0000
Accounts Payables994K(393K)6K788K
Other Working Capital(199K)7.1M11.17M(11.85M)
Other Non-Cash Items77K16.6M1.27M(1.1M)
Operating Cash Flow(36.18M)(37.36M)(51.52M)(81.63M)
Capital Expenditures(103K)(166K)(366K)(719K)
Acquisitions (Net)0000
Purchases of Investments0(100K)0(154.75M)
Sales of Investments00060.25M
Other Investing Activities0000
Investing Cash Flow(103K)(266K)(366K)(95.22M)
Debt Repayment2.5M35M(6M)(6M)
Common Stock Issued44K0221.62M17.87M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities(45K)(59K)(4.42M)(400K)
Financing Cash Flow2.5M34.94M381.2M11.47M
Effect of Forex Changes246K081K(87K)
Net Change in Cash(33.54M)(2.69M)329.39M(165.46M)
Free Cash Flow(36.28M)(37.53M)(51.89M)(82.35M)

BioAge Labs, Inc.

NASDAQ:BIOA

Intrinsic Alpha fair value

Locked

Current Price

$4.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.